Market Overview

Bank of America Comments on BCRX Phase-3 Data

Bank of America has published a report on BioCryst Pharmaceuticals (NASDAQ: BCRX) commenting on the status of phase-3 gout drug (BCX4208).

Posted-In: Bank of AmericaNews Reiteration FDA Analyst Ratings

 

Related Articles (BCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters